Monoclonal antibodies in immune and inflammatory diseases

Current Opinion in Biotechnology

Volumn 13, Issue 6, 2002, Pages 615-620

  Andreakos, Evangelos ^a   Taylor, Peter C ^a   Feldmann, Marc ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; CYTOKINE; ETANERCEPT; FC RECEPTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN F(AB) FRAGMENT; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; LENERCEPT; METHOTREXATE; MONOCLONAL ANTIBODY; PROTEIN P55; PROTEIN P75; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANTIBODY ENGINEERING; CLINICAL TRIAL; CROHN DISEASE; DRUG EFFICACY; DRUG SAFETY; GRAFT REJECTION; HUMAN; IMMUNE SYSTEM; INFLAMMATORY DISEASE; NONHUMAN; PRIORITY JOURNAL; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SPONDYLOARTHROPATHY; ACTIVE IMMUNIZATION; AUTOIMMUNE DISEASE; CHILD; DRUG APPROVAL; INFLAMMATION; METHODOLOGY; NEUROLOGIC DISEASE;

ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; AUTOIMMUNE DISEASES OF THE NERVOUS SYSTEM; CHILD; CLINICAL TRIALS; CROHN DISEASE; DRUG APPROVAL; GRAFT REJECTION; HUMANS; IMMUNOTHERAPY, ACTIVE; INFLAMMATION;

EID: 0036898145     PISSN: 09581669     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0958-1669(02)00355-5     Document Type: Review

References (69)

1. Andreakos E.T., Foxwell B.M., Brennan F.M., Maini R.N., Feldmann M. Cytokines and anti-cytokine biologicals in autoimmunity: present and future. Cytokine Growth Factor Rev. 13:2002;299-313.
2. Feldmann M., Maini R.N. Anti-TNF α therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol. 19:2001;163-196. This article reviews in detail the development of anti-TNF therapy in rheumatoid arthritis. It discusses how early observations placing TNFα at the apex of a pro-inflammatory cascade operating in rheumatoid synovium were reproduced in the clinic in patients, and how anti-TNFα trials have provided insight into the pathophysiology of rheumatoid arthritis.
3. Feldmann M. Development of anti-TNF therapy for rheumatoid arthritis. Nat Rev Immunol. 2:2002;364-371. A historical review of the development of anti-TNFα therapy for rheumatoid arthritis, from the early in vitro and in vivo animal models observations to the initiation of the clinical trials and the licensing of anti-TNFα mAbs.
4. Elliott M.J., Maini R.N., Feldmann M., Long-Fox A., Charles P., Katsikis P., Brennan F.M., Walker J., Bijl H., Ghrayeb J., et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α Arthritis Rheum. 36:1993;1681-1690.
5. Elliott M.J., Maini R.N., Feldmann M., Long-Fox A., Charles P., Bijl H., Woody J.N. Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet. 344:1994;1125-1127.
6. Elliott M.J., Maini R.N., Feldmann M., Kalden J.R., Antoni C., Smolen J.S., Leeb B., Breedveld F.C., Macfarlane J.D., Bijl H., et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet. 344:1994;1105-1110.
7. Maini R., St Clair E.W., Breedveld F., Furst D., Kalden J., Weisman M., Smolen J., Emery P., Harriman G., Feldmann M., et al. Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial. ATTRACT Study Group. Lancet. 354:1999;1932-1939.
8. Lipsky P.E., van der Heijde D.M., St Clair E.W., Furst D.E., Breedveld F.C., Kalden J.R., Smolen J.S., Weisman M., Emery P., Feldmann M., et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. New Engl J Med. 343:2000;1594-1602.
9. Kiely P.D., Johnson D.M. Infliximab and leflunomide combination therapy in rheumatoid arthritis: an open-label study. Rheumatology. 41:2002;631-637.
10. Rankin E.C., Choy E.H., Kassimos D., Kingsley G.H., Sopwith A.M., Isenberg D.A., Panayi G.S. The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. Br J Rheumatol. 34:1995;334-342.
11. Sander O., Rau R., van Riel P., van de Putte L., Hasler F., Baudin M., Ludin E., McAuliffe T., Dickinson S., Kahny M.-R., et al. Neutralization of TNF by Lenercept (TNFR55-IgG1, Ro 45-2081) in patients with rheumatoid arthritis treated for three months: results of a European phase II trial. Arthritis Rheum. 39:1996;S242.
12. Moreland L.W., Baumgartner S.W., Schiff M.H., Tindall E.A., Fleischmann R.M., Weaver A.L., Ettlinger R.E., Cohen S., Koopman W.J., Mohler K., et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. New Engl J Med. 337:1997;141-147.
13. Weinblatt M.E., Kremer J.M., Bankhurst A.D., Bulpitt K.J., Fleischmann R.M., Fox R.I., Jackson C.G., Lange M., Burge D.J. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. New Engl J Med. 340:1999;253-259.
14. Barrera P., Joosten L.A., den Broeder A.A., van de Putte L.B., van Riel P.L., van den Berg W.B. Effects of treatment with a fully human anti-tumour necrosis factor alpha monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNFalpha in patients with rheumatoid arthritis. Ann Rheum Dis. 60:2001;660-669.
15. den Broeder A.A., Joosten L.A., Saxne T., Heinegard D., Fenner H., Miltenburg A.M., Frasa W.L., van Tits L.J., Buurman W.A., van Riel P.L., et al. Long term anti-tumour necrosis factor alpha monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation. Ann Rheum Dis. 61:2002;311-318. The effect of adalimumab (D2E7), a fully human anti-TNFα monoclonal antibody, on the radiological course in rheumatoid arthritis (RA) was studied. In parallel, the prognostic value of markers of cartilage turnover and endothelial activation in the course of bone damage was examined. It was found that a total of 15/36 (42%) patients presented no radiological progression after two years. More patients with stable radiological course were still receiving anti-TNFα treatment after two years (13/15 [87%] versus 11/21 [52%]; p = 0.03) and had lower baseline COMP (cartilage oligomeric matrix protein) and soluble ICAM-1 (sICAM-1) levels (p = 0.01 and 0.04, respectively) than those in the group with progressive disease. In a logistic regression model the combination of sustained TNF neutralization and baseline COMP and sICAM-1 levels could be predictive of radiological outcome (p = 0.03). These results suggest that long term monotherapy with adalimumab has a positive effect on the radiological outcome and modulates cartilage and synovium turnover as measured by biological markers. Baseline serum sICAM-1 levels and COMP levels could be useful in identifying patients with progressive or non-progressive radiological outcome.
16. Davis M.W., Feige U., Bendele A.M., Martin S.W., Edwards C.K. III. Treatment of rheumatoid arthritis with PEGylated recombinant human soluble tumour necrosis factor receptor type I: a clinical update. Ann Rheum Dis. 59:(Suppl 1):2000;41-43.
17. Hazleman B., Smith M., Moss K., Lisi L., Scott D., Sopwith M., Choy E., Isenberg D. Efficacy of a novel PEGylated humanised anti-TNF fragment (CDP870) in patients with rheumatoid arthritis. Rheumatology. 39:2000;87.
18. Keane J., Gershon S., Wise R.P., Mirabile-Levens E., Kasznica J., Schwieterman W.D., Siegel J.N., Braun M.M. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. New Engl J Med. 345:2001;1098-1104. All reports of tuberculosis after infliximab therapy received (up to May 2001) through the MedWatch spontaneous reporting system of the Food and Drug Administration were analyzed. There were 70 reported cases of tuberculosis after treatment with infliximab, for a median of 12 weeks. This reported frequency of tuberculosis in association with infliximab therapy was much higher than the reported frequency of other opportunistic infections associated with this drug. In addition, the rate of reported cases of tuberculosis among patients treated with infliximab was higher than the available background rates. This study indicates that active tuberculosis can develop soon after the initiation of treatment with infliximab. Thus, physicians should screen patients for latent tuberculosis infection or disease before prescribing infliximab.
19. Drevlow B.E., Lovis R., Haag M.A., Sinacore J.M., Jacobs C., Blosche C., Landay A., Moreland L.W., Pope R.M. Recombinant human interleukin-1 receptor type I in the treatment of patients with active rheumatoid arthritis. Arthritis Rheum. 39:1996;257-265.
20. Bresnihan B., Alvaro-Gracia J.M., Cobby M., Doherty M., Domljan Z., Emery P., Nuki G., Pavelka K., Rau R., Rozman B., et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. 41:1998;2196-2204.
21. Jiang Y., Genant H.K., Watt I., Cobby M., Bresnihan B., Aitchison R., McCabe D. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum. 43:2000;1001-1009.
22. Cohen S., Hurd E., Cush J., Schiff M., Weinblatt M.E., Moreland L.W., Kremer J., Bear M.B., Rich W.J., McCabe D. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 46:2002;614-624. The efficacy and safety of anakinra (a non-antibody antagonist of IL-1) in combination with methotrexate (MTX) in patients with active rheumatoid arthritis (RA) was evaluated in a multicenter, randomized, double-blind, placebo-controlled trial. Patients with moderate-to-severe active RA who were receiving MTX for six consecutive months, with stable doses for greater than or equal to three months (those with disease duration of >six months but <12 years) were randomized into six groups: placebo or 0.04, 0.1, 0.4, 1.0 or 2.0 mg/kg of anakinra administered in a single, daily, subcutaneous injection. At week 12, the ACR20 (American College of Rheumatology) responses in the five active treatment plus MTX groups demonstrated a statistically significant (P = 0.001) dose-response relationship compared with the ACR20 response in the placebo plus MTX group. The ACR20 response rate in the anakinra 1.0 mg/kg (46%) and 2.0 mg/kg (38%) dose groups was significantly greater than that in the placebo group (19%). The ACR20 responses at 24 weeks were consistent with those at 12 weeks. These results suggest that in active RA patients, the combination of anakinra and MTX is safe and well tolerated and provides significantly greater clinical benefit than MTX alone.
23. Wendling D., Racadot E., Wijdenes J. Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody. J Rheumatol. 20:1993;259-262.
24. Yoshizaki K., Nishimoto N., Mihara M., Kishimoto T. Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody. Springer Semin Immunopathol. 20:1998;247-259.
25. Kavanaugh A.F., Davis L.S., Nichols L.A., Norris S.H., Rothlein R., Scharschmidt L.A., Lipsky P.E. Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule 1. Arthritis Rheum. 37:1994;992-999.
26. Kavanaugh A.F., Davis L.S., Jain R.I., Nichols L.A., Norris S.H., Lipsky P.E. A phase I/II open label study of the safety and efficacy of an anti-ICAM-1 (intercellular adhesion molecule-1; CD54) monoclonal antibody in early rheumatoid arthritis. J Rheumatol. 23:1996;1338-1344.
27. Kavanaugh A.F., Schulze-Koops H., Davis L.S., Lipsky P.E. Repeat treatment of rheumatoid arthritis patients with a murine anti-intercellular adhesion molecule 1 monoclonal antibody. Arthritis Rheum. 40:1997;849-853.
28. Kirkham B.W., Thien F., Pelton B.K., Pitzalis C., Amlot P., Denman A.M., Panayi G.S. Chimeric CD7 monoclonal antibody therapy in rheumatoid arthritis. J Rheumatol. 19:1992;1348-1352.
29. Olsen N.J., Brooks R.H., Cush J.J., Lipsky P.E., St Clair E.W., Matteson E.L., Gold K.N., Cannon G.W., Jackson C.G., McCune W.J., et al. A double-blind, placebo-controlled study of anti-CD5 immunoconjugate in patients with rheumatoid arthritis. The Xoma RA Investigator Group. Arthritis Rheum. 39:1996;1102-1108.
30. Isaacs J.D., Manna V.K., Rapson N., Bulpitt K.J., Hazleman B.L., Matteson E.L., St Clair E.W., Schnitzer T.J., Johnston J.M. CAMPATH-1H in rheumatoid arthritis - An intravenous dose-ranging study. Br J Rheumatol. 35:1996;231-240.
31. Choy E.H., Chikanza I.C., Kingsley G.H., Corrigall V., Panayi G.S. Treatment of rheumatoid arthritis with single dose or weekly pulses of chimeric anti-CD4 monoclonal antibody. Scand J Immunol. 36:1992;291-298.
32. Choy E.H., Connolly D.J., Rapson N., Jeal S., Brown J.C., Kingsley G.H., Panayi G.S., Johnston J.M. Pharmacokinetic, pharmacodynamic and clinical effects of a humanized IgG1 anti-CD4 monoclonal antibody in the peripheral blood and synovial fluid of rheumatoid arthritis patients. Rheumatology. 39:2000;1139-1146.
33. Veale D.J., Reece R.J., Parsons W., Radjenovic A., O'Connor P.J., Orgles C.S., Berry E., Ridgway J.P., Mason U., Boylston A.W., et al. Intra-articular primatised anti-CD4: efficacy in resistant rheumatoid knees. A study of combined arthroscopy, magnetic resonance imaging, and histology. Ann Rheum Dis. 58:1999;342-349.
34. Targan S.R., Hanauer S.B., van Deventer S.J., Mayer L., Present D.H., Braakman T., DeWoody K.L., Schaible T.F., Rutgeerts P.J. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. Crohn's Disease cA2 Study Group. New Engl J Med. 337:1997;1029-1035.
35. D'Haens G., Van Deventer S., Van Hogezand R., Chalmers D., Kothe C., Baert F., Braakman T., Schaible T., Geboes K., Rutgeerts P. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial. Gastroenterology. 116:1999;1029-1034.
36. Baert F.J., D'Haens G.R., Peeters M., Hiele M.I., Schaible T.F., Shealy D., Geboes K., Rutgeerts P.J. Tumor necrosis factor α antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology. 116:1999;22-28.
37. Rutgeerts P., D'Haens G., Targan S., Vasiliauskas E., Hanauer S.B., Present D.H., Mayer L., Van Hogezand R.A., Braakman T., DeWoody K.L., et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology. 117:1999;761-769.
38. Hanauer S.B., Feagan B.G., Lichtenstein G.R., Mayer L.F., Schreiber S., Colombel J.F., Rachmilewitz D., Wolf D.C., Olson A., Bao W., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 359:2002;1541-1549.
39. Present D.H., Rutgeerts P., Targan S., Hanauer S.B., Mayer L., van Hogezand R.A., Podolsky D.K., Sands B.E., Braakman T., DeWoody K.L., et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. New Engl J Med. 340:1999;1398-1405.
40. Sandborn W.J., Feagan B.G., Hanauer S.B., Present D.H., Sutherland L.R., Kamm M.A., Wolf D.C., Baker J.P., Hawkey C., Archambault A., et al. An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial. Gastroenterology. 120:2001;1330-1338.
41. D'Haens G., Swijsen C., Noman M., Lemmens L., Ceuppens J., Agbahiwe H., Geboes K., Rutgeerts P. Etanercept in the treatment of active refractory Crohn's disease: a single-center pilot trial. Am J Gastroenterol. 96:2001;2564-2568.
42. Sandborn W.J., Hanauer S.B., Katz S., Safdi M., Wolf D.G., Baerg R.D., Tremaine W.J., Johnson T., Diehl N.N., Zinsmeister A.R. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 121:2001;1088-1094.
43. van ben Bosch F., Beaten D., Kruithof F., De Keyser F., Mielants H., Veys E.M. Treatment of active spondyloarthropathy with infliximab, the chimeric monoclonal antibody to tumour necrosis factor α Ann Rheum Dis. 60:2001;iii33-iii36.
44. Kruithof E., Van den Bosch F., Baeten D., Herssens A., De Keyser F., Mielants H., Veys E.M. Repeated infusions of infliximab, a chimeric anti-TNFα monoclonal antibody, in patients with active spondyloarthropathy: one year follow up. Ann Rheum Dis. 61:2002;207-212.
45. Brandt J., Haibel H., Reddig J., Sieper J., Braun J. Successful short-term treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor-alpha monoclonal antibody infliximab. J Rheumatol. 29:2002;118-122.
46. Braun J., Brandt J., Listing J., Zink A., Alten R., Golder W., Gromnica-Ihle E., Kellner H., Krause A., Schneider M., et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet. 359:2002;1187-1193. The efficacy of infliximab, an antibody to TNFα, in treatment of active ankylosing spondylitis was assessed. In a 12-week placebo-controlled multicentre study, 70 patients were randomized in two equal groups: one group received intravenous infliximab (5 mg/kg) and the other group received placebo control at weeks zero, two and six. It was found that 53% patients on infliximab had a regression of disease activity at week 12 of at least 50% compared with 9% of patients receiving placebo. Function and quality of life also improved significantly on infliximab but not on placebo. These results show that treatment with infliximab is well tolerated and effective in patients with active ankylosing spondylitis.
47. Gorman J.D., Sack K.E., Davis J.C. Etanercept in the treatment of ankylosing spondylitis: a randomized, double-blind, placebo-controlled study. Arthritis Rheum. 43:2000;S403.
48. Lovell D.J., Giannini E.H., Reiff A., Cawkwell G.D., Silverman E.D., Nocton J.J., Stein L.D., Gedalia A., Ilowite N.T., Wallace C.A., et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. New Engl J Med. 342:2000;763-769.
49. Kietz D.A., Pepmueller P.H., Moore T.L. Therapeutic use of etanercept in polyarticular course juvenile idiopathic arthritis over a two year period. Ann Rheum Dis. 61:2002;171-173.
50. Chaudhari U., Romano P., Mulcahy L.D., Dooley L.T., Baker D.G., Gottlieb A.B. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet. 357:2001;1842-1847. A double-blind, randomized trial to assess the clinical benefit and safety of infliximab in plaque-type psoriasis was performed. Patients with moderate to severe plaque psoriasis were randomly assigned intravenous placebo, infliximab 5 mg/kg, or infliximab 10 mg/kg at weeks zero, two and six. Patients were assessed at week 10 for the primary endpoint (score on the physician's global assessment [PGA]). Analysis was by intention to treat. Of the 33 patients enrolled, three dropped out. It was found that 82% of patients in the infliximab 5 mg/kg group were responders, compared with 18% in the placebo group and 91% of patients in the infliximab 10 mg/kg group. Thus, infliximab administration as a monotherapy results in a high degree of clinical benefit and rapid time to response in the treatment of moderate to severe plaque psoriasis. These findings suggest that TNFα has a pivotal role in the pathogenesis of psoriasis.
51. Mease P.J. Tumour necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors. Ann Rheum Dis. 61:2002;298-304.
52. Mease P.J., Goffe B.S., Metz J., VanderStoep A., Finck B., Burge D.J. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 356:2000;385-390.
53. Stone J.H., Uhlfelder M.L., Hellmann D.B., Crook S., Bedocs N.M., Hoffman G.S. Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety. Arthritis Rheum. 44:2001;1149-1154.
54. Weinblatt M.E., Maier A.L., Overmann S.S., Mease P.J., Fraser P.A., Gravallese E.M. Etanercept in Still's disease in the adult. Arthritis Rheum. 43:2000;S391.
55. Ellman M.H., MacDonald P.A., Hayes F.A. Etanercept as treatment for diffuse scleroderma: a pilot study. Arthritis Rheum. 43:2000;S392.
56. Reiff A., Takei S., Sadeghi S., Stout A., Shaham B., Bernstein B., Gallagher K., Stout T. Etanercept therapy in children with treatment-resistant uveitis. Arthritis Rheum. 44:2001;1411-1415.
57. Nussenblatt R.B., Fortin E., Schiffman R., Rizzo L., Smith J., Van Veldhuisen P., Sran P., Yaffe A., Goldman C.K., Waldmann T.A., et al. Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial. Proc Natl Acad Sci USA. 96:1999;7462-7466.
58. Tubridy N., Behan P.O., Capildeo R., Chaudhuri A., Forbes R., Hawkins C.P., Hughes R.A., Palace J., Sharrack B., Swingler R., et al. The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group. Neurology. 53:1999;466-472.
59. Abrams J.R., Lebwohl M.G., Guzzo C.A., Jegasothy B.V., Goldfarb M.T., Goffe B.S., Menter A., Lowe N.J., Krueger G., Brown M.J., et al. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest. 103:1999;1243-1252.
60. +) counts and in the number of memory effector T lymphocytes was observed in alefacept-treated patients and correlated with disease improvement. These findings suggest that alefacept is efficacious in the treatment of chronic plaque psoriasis, and in some patients results in sustained benefit even after the cessation of treatment.
61. Davis J.C. Jr, Totoritis M.C., Rosenberg J., Sklenar T.A., Wofsy D. Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus. J Rheumatol. 28:2001;95-101.
62. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. New Engl J Med. 313:1985;337-342.
63. Vincenti F., Nashan B., Light S. Daclizumab: outcome of phase III trials and mechanism of action. Double Therapy and the Triple Therapy Study Groups. Transplant Proc. 30:1998;2155-2158.
64. Nashan B., Light S., Hardie I.R., Lin A., Johnson J.R. Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group. Transplantation. 67:1999;110-115.
65. Nashan B., Moore R., Amlot P., Schmidt A.G., Abeywickrama K., Soulillou J.P. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group. Lancet. 350:1997;1193-1198.
66. Beniaminovitz A., Itescu S., Lietz K., Donovan M., Burke E.M., Groff B.D., Edwards N., Mancini D.M. Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody. New Engl J Med. 342:2000;613-619.
67. Przepiorka D., Kernan N.A., Ippoliti C., Papadopoulos E.B., Giralt S., Khouri I., Lu J.G., Gajewski J., Durett A., Cleary K., et al. Daclizumab, a humanized anti-interleukin-2 receptor α chain antibody, for treatment of acute graft-versus-host disease. Blood. 95:2000;83-89.
68. Kobbe G., Schneider P., Rohr U., Fenk R., Neumann F., Aivado M., Dietze L., Kronenwett R., Hunerliturkoglu A., Haas R. Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse antiTNFα antibody. Bone Marrow Transplant. 28:2001;47-49.
69. Chiang K.Y., Abhyankar S., Bridges K., Godder K., Henslee-Downey J.P. Recombinant human tumor necrosis factor receptor fusion protein as complementary treatment for chronic graft-versus-host disease. Transplantation. 73:2002;665-667. In an open label study, the efficacy of etanercept (Enbrel) in the treatment of steroid-dependent chronic graft-versus-host (GvHD) disease was investigated. Etanercept was given as a subcutaneous injection twice weekly for four weeks followed by once weekly for four more weeks, and progression or regression of chronic GvHD was monitored. At the end of the eight week treatment course, 80% of the patients had no adverse side effects, and 70% of them showed improvement. These results indicate that TNFα plays an important role in the pathophysiology of chronic GvHD and that etanercept may be beneficial for its treatment. Additional studies should be performed to optimize etanercept as a potential complementary therapy for resolution of steroid-dependent chronic GvHD.